Eyenovia reports Q3 2022 net loss of $7.3M; MicroLine VISION-2 Phase 3 trial meets primary endpoint

HYPERION DEFI, INC.

2022-Q3 EPS reported -$0.67

Net loss of $7.3M ($0.21 per share) vs $5.6M loss in Q3 2021; cash $25.3M (incl. $7.9M restricted) as of Sep 30, 2022.
VISION-2 trial achieved primary endpoint: statistically significant ≥15-letter DCNVA improvement at 2 hours; FDA meeting planned.
Michael Rowe appointed CEO (former COO) and to Board of Directors; manufacturing facility in Redwood City, CA now operational.
Arctic Vision Phase 3 trial of MicroLine in China enrolling patients; expects completion in late 2023.
Collaboration with Bausch+Lomb and Optejet out-licensing progress noted; company evaluating additional partnerships.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

HYPERION DEFI, INC. reported third quarter ended September 30, 2022 results: net income net loss was approximately $(7.3) million, or $(0.21) per share, EPS $(0.21) per share.

Period: third quarter ended September 30, 2022
Net income: net loss was approximately $(7.3) million, or $(0.21) per share
EPS: $(0.21) per share
Result: reported results

Exact text from the filing

Eyenovia, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022.

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

HYPERION DEFI, INC. filing history →

Source: SEC EDGAR

accession 0001104659-22-117172

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.